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Microvascular free flaps are key components of reconstructive surgery, but despite their
common use and usual reliability, flap failures still occur. Many pharmacological agents
have been utilized to minimize risk of flap failure caused by thrombosis. However,
the challenge of most antithrombotic therapy lies in providing patients with optimal an-
tithrombotic prophylaxis without adverse bleeding effects. There is a limited but growing
body of evidence suggesting that the vasoprotective and anti-inflammatory actions of
statins can be beneficial for free flap survival. By inhibiting mevalonic acid, the down-
stream effects of statins include reduction of inflammation, reduced thrombogenicity,
and improved vasodilation. This review provides a summary of the pathophysiology of
thrombus formation and the current evidence of anticoagulation practices with aspirin,
heparin, and dextran. In addition, the potential benefits of statins in the perioperative
management of free flaps are highlighted.
Free flaps have become a common technique to transfer tissue, such as skin, fat, fas-
cia, muscle, and/or bone, together with its blood supply. Microvascular free-tissue transfers
are often used in an attempt to restore complex congenital, ablative, and traumatic tissue
defects, and the survival of the flap is highly dependent on the patency of the microvas-
cular anastomosis.1,2 During surgery, the arterial and venous blood flow is reconnected
using microsurgical techniques. These techniques are based on standard vascular surgery
principles, on a microscopic level. Murphy3 performed the first successful vascular anas-
tomosis as early as 1897. In 1902, Carrel4 described the method for triangulation of blood
vessels in arterial and venous repair, and in 1960, Jacobson and Suarez5 created micro-
surgical anastomoses in laboratory animals, coining the term “microvascular surgery.”
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Reconstructive microsurgery was born in the garage of Dr Harry Buncke in 1964, when
he reported a successful replantation of a rabbit ear with 1-mm vessels.6 Buncke, and
his homemade instruments, unlocked the door to modern-day microsurgical techniques.
Initially, free flap surgery was restricted by high failure rates, long operative times, and
a limited number of trained surgeons, but advances in surgical techniques and equipment
have decreased the rates of complications. However, despite the current reliability of mi-
crosurgical free-tissue transfers, flap failures still arise. Such failures are most commonly
related to thrombosis occurring at the arterial or venous anastomosis, often resulting from
technical errors. Approximately 10% of microvascular free flaps suffer complications, and
flaps that undergo reexploration can be salvaged at a 50% to 80% success rate, making the
overall success rate for free flaps up to 98% among experienced surgeons.7-9 Nonetheless,
anastomotic thrombosis still remains a major complication of microsurgical free-tissue
transfers and total flap loss due to thrombi remains a significant concern.10
To inhibit the formation of microvascular thrombi, many surgeons routinely use pre-
emptive anticoagulants and/or vasodilators.1,11,12 Approximately 96% of surgeons reported
use of some types of anticoagulation regimen, and the protocols vary widely among
surgeons.13 The most commonly used pharmacological agents are aspirin, heparin, and
dextran, but their usage is often based on the surgeon’s experience and without agreement
in the timing or dosing. In fact, an early review of anticoagulation practices around the
world point to anecdotal experience with more than 20 different agents used, most with
very limited data supporting their benefit.14 Although some of the pharmacological agents
have been studied experimentally, most of the data come from animal studies or retrospec-
tive studies, with only a few prospective randomized trials. In addition, new drug such as
statins have emerged as pharmacological agents that are used to prevent the formation of
microvascular thrombosis. There is a growing body of evidence that suggest that the vaso-
protective and anti-inflammatory actions of statins can be beneficial for free flap survival,
but their role in preventing anastomotic thrombosis is not known. This article provides a
summary of the pathophysiology of thrombus formation and reviews the current evidence
of anticoagulation practices with aspirin, heparin, and dextran. We revisit the literature
concerning the utility of pharmacological treatments used to improve free flap survival and
review the utility of pharmacological agents not traditionally thought of as anticoagulants.
PATHOPHYSIOLOGY OF THROMBOSIS
The formation of thrombi is the body’s defense mechanism to prevent blood loss after injury.
Thrombosis is highly regulated through a complex interplay between the vascular endothe-
lium, platelets, various molecular receptor, and inflammatory mediators. The microvascular
anastomosis injures the vascular intima, causing the body to employ platelets and fibrin to
seal the vascular defect. The time course of the development of a flow-occlusive thrombus
is dependent on a multitude of factors, and the literature reveals that little is known about
the underlying mechanisms. Limited evidence points out that 90% of arterial thrombi and
42% of venous thrombi in free flaps occur on postoperative day 1. The risk for anastomotic
thrombosis is highest during the first 2 postoperative days and decreases to 10% after post-
operative day 3.11,12,15 In agreement with these clinical observations, Chien et al16 showed
that 95% of flap reexplorations were made during the first 72-hour postoperative period.
Better knowledge of the mechanism and time course of thrombus formation in venous and
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Figure 1. Overview of the mechanism of action. Inhibition of HMG CoA modulates cell infiltrate,
decreases coagulation and promotes vasodilation. CoA indicates coenzyme A; CRP, C-reactive
protein; HMG-CoA, 3-hydroxy-methylglutaryl coenzyme A; MHC-II, major histocompatibility
complex class II; NF-κB, nuclear factors kappa beta; NO, nitric oxide; and eNOS, endothelial NO
synthase.
arterial anastomoses is essential in directing the appropriate perioperative pharmacological
treatment as a means to reduce ischemic tissue injury and ultimately flap failure.
Studies have shown that the content of microvascular thrombi differs between venous
and arterial occlusions, making the choice of antithrombotic agent particularly important.17
Platelet aggregation is believed to be the underlying cause of arterial thrombosis, whereas
venous thrombosis is primarily the result of fibrin clotting. In microvascular tissue transfer,
venous thrombosis causes flap failure more frequently than arterial thrombosis, making
fibrin depositions a more significant factor. Khouri et al17 showed that microvascular venous
thrombi contained more fibrin than platelets and theoretically identified heparin as the better
anticoagulant by selectively inhibiting platelet aggregation and fibrin deposition. Although
other reports support the finding of Khouri et al, they also detected a higher content of
platelets in arterial thrombi, making aspirin the preferred agent.18 However, on the basis
of the finding of equal content of both fibrin strands and platelet aggregates in thrombi on
electron microscopy, Savoie et al19 suggested the use of both aspirin and heparin in the
prevention of anastomotic thrombi.
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The difference in composition between arterial and venous thrombi can be attributed to
the mechanisms of primary and secondary hemostasis. Primary hemostasis is initiated upon
endothelial damage, exposing the normally isolated subendothelial collagen to circulating
platelets. Platelets initially aggregate using the specific glycoprotein receptor Ia/IIa, and
the adhesion is further strengthened by von Willebrand factor (vWF). Activated platelets
release granules containing ADP, platelet-activating factor, serotonin, platelet factor 2, vWF,
and thromboxane A2 (TXA2), which, in turn, activate additional platelets, increasing their
binding to fibrinogen via glycoprotein IIb/IIIa. Secondary hemostasis occurs simultaneously
and utilizes activated platelets and tissue factor (TF) to initiate the coagulation cascade.
Secondary hemostasis results in the formation of fibrin strands and is believed to propagate
the formation of venous thrombi.20,21 However, not mutually exclusive, the 2 processes are
linked via multiple factors and seem to affect vascular patency through the formation of
fibrin strands and platelet plugs.
ANTICOAGULANTS IN FREE FLAP SURGERY
The addition of pharmacological anticoagulants in patients undergoing microvascular free-
tissue transfers has become a mainstay of perioperative management (Table 1). Clinical
observations have suggested that antithrombotic therapy significantly reduces the morbidity
after microsurgical free-tissue transfers.22 It was proposed as early as 1978 by Ketchum23
that the outcome of free flap transfer could be improved by the addition of agents that
decreased platelet function, increase blood flow or decrease blood viscosity, and counteract
the effects of thrombin on platelets and fibrinogen. Chen et al24,25 have described the ideal
antithrombotic agent as an easily administered anticoagulant that successfully prevents
thrombosis, with minimal side effects and low rates of complications. However, to date, none
of the available pharmaceutical agents have successfully met all the criteria listed previously.
Aspirin
Aspirin is a potent anticoagulant used to decrease graft or vascular occlusion for a range
of vascular procedures. Aspirin acetylates and thereby irreversibly inhibits cyclooxygenase
(COX), which is the enzyme required for the formation of both prostaglandins and TXA2.
Prostaglandins are potent vasodilators that inhibit platelet aggregation, whereas TXA2 both
vasoconstricts and enhances platelet aggregation. Aspirin is rapidly absorbed in the upper
gastrointestinal (GI) tract, and one of aspirin’s major advantages is that it inhibits platelet
function within 60 minutes of administration. In addition, the irreversible inhibition of COX
results in decreased platelet aggregation for up to 10 days, which approximates the normal
life span of a platelet.
Despite a relatively favorable safety profile, aspirin usage can be associated with
various complications. Data from coronary artery bypass graft surgery show increased
intraoperative blood loss and transfusion requirements with preoperative use of aspirin.26
In addition, inhibition of COX leads to lower levels of prostaglandin E2 (PGE2) and the
subsequent loss of the protective effects of PGE2 on the gastric mucosa leads to the GI side
effects associated with aspirin use. Specifically, aspirin use has been shown to increase the
risk of GI bleeding, even in low doses.27 Other rare, but serious, complications attributed to
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aspirin usage are hemorrhagic stroke and increased sensitivity resulting in urticaria, rhinitis,
and bronchoconstriction.
With regard to the prevention of thrombosis, no associated dose response has been
shown for aspirin but higher doses increase the rate of GI side effects. Although studies in
healthy patients and those with atherosclerotic disease have shown that 100 mg of aspirin
effectively inhibits TXA2, previously reported anticoagulation protocols in microvascular
surgery cite doses ranging from 250 mg every 3 days to as high as 1500 mg daily. However,
low-dose aspirin (5 mg/kg) administered via intra-arterial infusion in an arterial and venous
anastomoses rat model has been shown to successfully reduce thrombus formation and
maintain the patency of the microcirculation. The benefit of low-dose aspirin is that it does
not affect the COX of endothelial or smooth muscle cells, thereby leading fewer systemic
side effects.28,29
There are no prospective randomized trials evaluating the benefit of aspirin adminis-
tration in microvascular tissue transfer. In a retrospective chart study, Chien et al16 found
that flap survival rates in patients undergoing head and neck reconstruction using coadmin-
istrating aspirin with subcutaneous heparin were equivalent to the free flap survival rates
in patients using other anticoagulation agents. Basile et al30 showed that ticlopidine, an
ADP receptor inhibitor, administered alone or in combination with aspirin, significantly
increased the 1-hour patency rate in an animal thrombosis model. Unfortunately, the clinical
utility of the combination treatment was never established. Therefore, recommendations
for the use of aspirin in microvascular surgery are primarily based on animal models and
on observations in cardiac and vascular surgery practices where a protective effect of as-
pirin against postoperative death, stroke, myocardial infarction, and vascular occlusion was
shown. In addition, a preventive effect of aspirin on the formation of microvascular venous
or arterial thrombosis in free-tissue transfers has not yet been shown, putting the use of
aspirin in free flap surgery in question.
Heparin and low-molecular-weight heparin
Heparin is a glycosaminoglycan, clinically used in the prevention of both arterial and venous
thromboses.31 Heparin, and its low-molecular derivatives, binds to antithrombin, thereby
causing a conformational change that increases the affinity of antithrombin to its substrate
by a 1000-fold. Activated antithrombin inactivates coagulation factors II (thrombin), IX, X,
XI, and XII, resulting in decreased thrombosis formation. In addition, inactivation of throm-
bin by antithrombin leads to reduced levels of coagulation factors V and VII, decreased
recruitment of platelets, and reduced cross-linking of fibrin. The antithrombotic effect of
heparin is clinically measured by an increase in clotting time and expressed as prolonged
activated partial thromboplastin time (aPTT). When administered in large doses, heparin
stimulates endothelial cells to produce nitric oxide (NO), leading to increased vasodilation.
Low-molecular-weight heparin (LMWH) is a derivative of heparin with the same thera-
peutic effect on the inhibition of factor X, giving LMWH the same efficacy as heparin in
preventing venous thrombosis. Because of its weaker inhibition of antithrombin, LMWH
has fewer adverse effects than heparin. Heparin and LMWH are often considered standard
of care in deep venous thromboembolism prophylaxis. However, because of conflicting
reports in the literature, there is still debate whether LMWH is as efficient as heparin in
preventing arterial thrombosis. Although some studies have clearly shown that LMWH is
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less effective than heparin in reducing the incidence of arterial thrombosis, other studies
have reported equal results. Studies comparing the effects of heparin and LMWH in a rat
model showed that both agents caused a similar increase in vessel patency of up to 50%
compared with untreated controls.32 Other studies yielded similar results showing equal
increase in free flap survival with the usage of heparin and LMWH, with the only notable
difference between the 2 agents being a higher rate of hematoma development in the heparin
group.33 In a rat arterial model, Malm et al34 addressed the specific concern of the ability
of LMWH to reduce the formation of arterial thrombi. LMWH was shown to prevented
arterial thrombosis, as effectively as heparin, but in contrast to heparin, LMWH did not
increase the incidence of bleeding.
One potential goal of anticoagulation therapy in free-tissue transfer is to deliver the
anticoagulant agent locally to the anastomotic site, thereby maintaining low systemic con-
centrations to reducing adverse effects. In animal studies, irrigation with a 100 U/mL
solution of heparin has been shown to increase the patency of microvascular anastomoses
at 24 hours, without a prolongation in aPTT.35 Fu and colleagues36 showed a significant
increased patency rate of vascular anastomoses after local administration of high concentra-
tions of heparin. Similarly, irrigation with heparin was shown to have a significant effect on
the reduction of thrombosis during first 7 days after surgery as compared with saline irriga-
tion alone and there was no observed difference in patency or side effects between heparin
and LMWH.25 In a similar study, heparin was administered locally to musculocutaneous
flaps after secondary venous ischemia and revascularization and flaps were randomized
to treatment with low-dose systemic heparin, local infusion, or untreated control. Local
heparin delivery resulted in complete survival of all flaps, whereas the control and systemic
heparin groups had flap failures of 60.8% and 62.1%, respectively.37 Topical application
also seems to have an effect on cutaneous free flaps. Sawada et al38 found that dorsal
ischemic rat flaps treated with topical heparin had an increase in flap survival compared
with areas not treated with heparin. Although these results are promising, no human studies
have shown favorable results with topical heparin or LMWH treatment.
Dextrans
Dextrans are a group of complex polysaccharides, with molecular weights ranging from
3 to 2000 kDa. Dextrans are synthesized by fermentation of sucrose by Leuconostoc
mesenteroides, and their discovery dates back to the mid-19th century when Louis Pasteur39
described dextran as a microbial product in wine. Dextrans are now commonly used to
decrease vascular thrombosis. The antithrombotic effects of dextrans are mediated by
several different mechanisms. Dextrans bind to erythrocytes, platelets, and endothelial cells,
thereby increasing their electronegativity and reducing aggregation and adhesion. Dextrans
also inhibit α-2 antiplasmin, thereby promoting thrombolysis.40 In addition, the larger
dextrans are excreted poorly from the kidney and the osmotic effects cause hemodilution
with improved blood flow that further increases the patency of the anastomosis.41
The administration of dextrans varies globally, and there is no controlled random-
ized trial available to support their recommended use or confirm a beneficial effect in free
flap survival.42 Although there are relatively few side effects associated with dextran use,
when adverse effects do occur, they can be very serious. These include anaphylactic re-
action, nephrotoxicity, pulmonary edema, and adult respiratory distress syndrome. Several
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Table 1. Overview of the mechanism of action of the most commonly used anticoagulant in free
flap surgery
Drug Mechanism of action
Levels of evidence in
free flap surgery
Aspirin Inhibits the enzyme cyclooxygenase, thereby preventing the formation
of both thromboxane and prostacyclin
Level IV
Heparin Bind to antithrombin and increases the affinity of antithrombin to its
substrate by a 1000-fold. Activated antithrombin inactivates
coagulation factors II (thrombin), IX, X, XI, and XII resulting in
decreased thrombosis formation.
Level IV
Dextran Bind to erythrocytes, platelets, and endothelial cells and increase their
electronegativity and reduce aggregation and adhesion. Dextrans also
inhibit α-2 antiplasmin, thereby promoting thrombolysis. The osmotic
effects cause hemodilution with improved blood flow.
Level IV
Statins Reduces inflammation, reduces thrombogenicity, and improves
vasodilation.
Level IV
institutions have found the rates of pulmonary edema to outweigh the benefits of dextrans,
consequently limiting their use in free flap surgery and in patients awaiting angioplasty.43,44
Given the added risk of serious side effects and a lack of data proving the efficacy of dex-
trans to reduce free flap failure, many practice habits back that of other institutions and
argue for cautious use of dextrans in free-tissue transfers.
STATINS AS PHARMACOLOGICAL AGENTS IN FREE FLAP SURGERY
3-Hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, otherwise
known as statins, are powerful inhibitors of cholesterol biosynthesis (Fig 1). Statins are
routinely used in the management of hyperlipidemia and have as such been established as a
major agent in the prevention of coronary artery disease, stroke, and ischemic events.45-47
Statins inhibit the conversion of HMG-CoA to 1-mevalonic acid, the rate-limiting step
of cholesterol synthesis. The inhibition of HMG-CoA reductase also leads to decreased
formation of several intermediates that are important in the regulation of endothelial cell
function.48,49 The inhibition of mevalonic acid synthesis prevents the synthesis of isoprenoid
intermediates of the cholesterol biosynthetic pathway.50 These intermediates are important
for the posttranslational modification of various proteins, including the γ -subunit of het-
erotrimeric G-proteins and small guanosine triphosphate–binding proteins such as Rho.51
Different statins have varying tissue permeability and metabolism, resulting in different po-
tencies for extrahepatic HMG-CoA reductase inhibition. The more lipophilic statins, such
as atorvastatin and simvastatin, enter the endothelial cells by passive diffusion, whereas the
hydrophobic statins, such as pravastatin and rosuvastatin, primarily target the liver.
The endothelium maintains vascular homeostasis by controlling inflammation and
coagulation, as well as regulating the vascular tone through the production of vasoactive
agents. During free flap surgery, the function of the endothelium can be altered. The
resulting endothelial dysfunction contributes to the formation of thrombi by inducing an
inflammatory state that is marked by a reduction of anticoagulant factors and an increase in
prothrombotic factors.52,53 Although it is known that a decrease in low-density lipoprotein
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(LDL) contributes to an improvement of endothelial dysfunction, in vivo studies have shown
that statins restore endothelial function in patients with hyperlipidemia and atherosclerosis
before decreasing lipid levels.54 These findings suggest additional mechanisms are involved
in the therapeutic effect of statins on the vascular endothelium.55-58 In addition, statins have
been shown to directly affect endothelial cell function and in vivo studies in a mouse
model have shown that satins can modify vessel relaxation.59 Statins have been shown to
exert their anticoagulative activities through several mechanisms that target inflammation,
coagulation, and vasoconstriction.
The majority of clinical data regarding inflammation and statins come from large
cohort studies in populations with hyperlipidemia and associated vascular and cardiovas-
cular diseases. Results of clinical trials such as CARE, LIPID, and HPS suggested that
the cardiovascular benefit of statins in part correlated only with the reduction of LDL and
went beyond the lipid-lowering properties, pointing to alternate pathways of action. Over
the years, culminating evidence has shown that one of the major effects of statins includes
the reversal of endothelial dysfunction exerted by the anti-inflammatory properties of
statin.49 A major component of the anti-inflammatory mechanism is the direct inhibition
of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1).60,61 The proinflammatory cytokines that are produced upon endothelial injury
facilitate leukocyte migration across the endothelium by increasing the expression of both
ICAM-1 and VCAM-1.62 The local inflammatory milieu is further established by the
production of the inflammatory cytokines IL-1, IL-6, tumor necrosis factor-alpha (TNF-α),
and transforming growth factor-beta (TGF-β) by leukocytes. Statins have been shown to
downregulate the adhesion molecules ICAM-1 and VCAM-1, thereby leading to decreased
neutrophil rolling, adherence, and migration across the endothelium.63,64 Moreover, statins
have been shown to inhibit the expression of major histocompatibility complex class II
(MHC-II) on endothelial cells and macrophages, thereby repressing T-cell activation.65
In addition to decreasing the inflammatory response, current data indicate that statins
can modulate the levels of the highly sensitive C-reactive protein (CRP).53 While previ-
ously thought of as an acute-phase reactant in inflammatory processes, recent studies have
shown that CRP can upregulate the expression of adhesion molecules and chemokines
in endothelial cells and act like a mediator of thrombosis following vascular injury.66,67
Statins have been shown to reduce CRP levels independent of the decrease in serum lipid
concentration.68 It has been confirmed by multiple prospective cohort studies that CRP
levels are useful predictors of myocardial infarction and stroke and serve as important
indicators of vascular and cardiovascular health.69
C-reactive protein has been identified as a leading biomarker of inflammation in
clinical setting and a strong independent predictor of future vascular events.70-73 It has
been suggested that the decreased levels of CRP seen with the use of statins mediate the
beneficial impact on the reduction of coronary events and the improved survival after acute
coronary syndrome.74,75 Data from the most recent JUPITER trial (Justification for the Use
of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) showed a reduction
in all vascular events by 44%, a 54% reduction in the rate of myocardial infarction and 48%
reduction in stroke, in a cohort of 17,802 patients with normal serum LDL levels (<130
mg/dL) and elevated CRP levels (≥2.0 mg/L) treated with rosuvastatin versus placebo.47
These findings support the anti-inflammatory effects of statins on the protection of vascular
health independent of lipid lowering.
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The prothrombotic state that follows endothelial dysfunction is characterized by an
activation of the extrinsic coagulation pathway, triggered by the release of TF. Coagulation
is further promoted by the inhibition of thrombolysis mediated by the increased levels of
plasminogen activator inhibitor-1 (PAF-1). Tissue factor is a glycoprotein that converts
factor X to factor Xa and is the principal initiator of the extrinsic coagulation pathway; TF
can be found in the subendothelial layers of the vessel wall. In addition, substantial amounts
of TF can be released by macrophages and monocytes after stimulation with inflammatory
cytokines.76 Upon injury of the vessel wall, the concentration of TF increases, thereby
initiating the coagulation cascade causing the formation of a thrombus. In vitro studies
have confirmed that the prevention of isoprenoid intermediate synthesis by statins is crucial
for the inhibition of TF. Although statins have traditionally not been used as anti-TF agents,
decreased expression of TF mRNA has been seen in macrophages, monocytes, and aortic
endothelial cells after the use of statins.77-79 Studies in in vivo atherosclerotic animal
models have shown a reduced TF expression with statin treatment that is independent of
lipid lowering.80-82 In addition to the results obtained in animal studies, the ATROCAP
(Atorvastatin and Thrombogenicity of the Carotid Atherosclerotic Plaque) study has shown
lower TF antigen levels and TF activity with low-dose atorvastatin compared with placebo,
pointing to a clinical utility of statins in reduction of TF and initiation of the coagulation
cascade.83 The inhibition of isoprenoid intermediates also explains the upregulation of
thrombomodulin (TM) by statins. These intermediates exert anticoagulant properties by
activating a cofactor in thrombin-induced activation of the protein C pathway.84 Statins
have been shown to increase TM mRNA levels in a dose-dependent manner using the Rho
signaling pathway.85
The endothelium promotes vasodilation by the production of NO by means of
endothelial NO synthase (eNOS). eNOS is the molecular factory of NO and its stability
and activity directly regulate the production of NO, a potent vasodilator and inhibitor of
platelet aggregation.86-88 Early landmark studies by Laufs et al89 demonstrated the ability
of statins to upregulate eNOS activity and increase NO production both under normal
conditions and after hypoxia. Through their inhibition of the mevalonate pathway, statins
inhibit isoprenoid production, which leads to altered posttranslational regulation of the Rho
signaling pathway.35 Rho modulates the activity of nuclear factors kappa beta (NF-κB) and
Kruppel-Like factor-2 (KLF2) and inhibits endothelial production of eNOS. By inhibiting
the isoprenylation of Rho and Rho kinase, statins increased eNOS expression, eNOS
mRNA stability, and thereby NO production.58,89-92 Statins can increase eNOA activity
by posttranslational activation of the phosphatidylinositol 3-kinase/protein kinase Akt
pathway.93 Activation of Akt is an important event in many cellular activities and Akt can
regulate eNOS activity, leading to increased NO production.94
Rat burn models have also been used as a means to study the effects of statins on the
endothelium. Zones of stasis, thought to develop from resulting heat injury to the endothe-
lium, were used by Uygur et al95 as a model to display the reduction in the vasoactive and
antithrombotic properties of the endothelium. Their model showed an impressive ability
of simvastatin to salvage zones of stasis. Published data showed statistically significant
difference in blood flow favoring simvastatin versus control group in burn interspaces,
whereas TM immunohistochemistry staining showed preservation of endothelial TM only
in the simvastatin group.95 Gross appearance of the tissue also displayed increased viability
in the simvastatin group compared with controls. On the basis of such experiments and the
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culmination of additional evidence on statins, a mechanism for tissue preservation might
stem from the statin-induced increase in vasoreactivtiy secondary to increased eNOS ex-
pression/RNA stability, NO production, and a simultaneously decreased rate of thrombosis
secondary to the upregulation/preservation of TM. Equally relevant in statin-induced anti-
coagulation were findings by Undas et al,96 who observed statistically significant reduction
of prothrombin activation products, factor Va and factor XIIIa, with simvastatin use over
a course of 3 months in patients with advanced coronary artery disease. The evidence
here points to a decreased activation in blood clotting with simvastatin independent of
cholesterol reduction.
In agreement with above-referenced studies, clinical studies in patients with atheroscle-
rosis have shown statistically significant effects of therapeutic doses of atorvastatin on Rho
kinase inhibition whereas additional studies with the Rho inhibitor fasudil have yielded sta-
tistically significant effects showing improved vasodilatation, as measured by endothelium-
dependent, flow-mediated brachial artery ultrasonography.97,98 These observations confirm
the findings of Laufs et al and add to the suggestion that inhibition of Rho/Rho kinase with
atorvastatin has the potential to contribute to an increase in baseline eNOS activity and NO
availability in clinical use outside of cell culture models.
The pathophysiology behind ischemic and ischemia-reperfusion (I/R) injuries seen
in solid organ transplantation is similar to that of free-tissue transfers and equally leads
to increased inflammation, coagulation, and vasoconstriction associated with endothelial
dysfunction.99,100 Of relevance to free-tissue transfers are the I/R injury in vivo animal mod-
els of myocardial ischemia, showing short-term cardioprotective effects of statins.101,102
This was attributed to the ability of statins to preserve the activation of eNOS immediately
after I/R injury. To further confirm the lipid independent effects of statins on I/R injury,
studies in normocholesterolemic rats have shown that statin pretreatment 18 hours prior to
induction of I/R injury has a protective effect on the myocardium while improving coro-
nary flow.103,104 Animal studies in I/R injuries have identified TNF-α as a key mediator in
endothelial dysfunction, and by decreasing the production of NO via the NF-κB pathway
and stimulating the production of oxygen free radicals, TNF-α further adds to the release
of inflammatory cytokines.105 This creates the same proinflammatory milieu thought to
contribute to endothelial dysfunction in atherosclerosis.
DISCUSSION
Microvascular free-tissue transfers are key procedures in reconstructive surgery. Although
the success rates for free flaps are increasing, studies have identified venous thrombosis,
and the resulting venous congestion, as the most common reason for flap failure. The
thrombotic events are often triggered by suboptimal microvascular anastomosis, pedicle
compression, infection, or donor-vessel mismatch. Several pharmacological agents have
been used in an attempt to improve flap survival, and agents such as aspirin, heparin, and
dextran are often added preoperatively in an attempt to prevent the formation of thrombi.
However, there are limited clinical studies supporting their use in free flaps and there is
currently no consensus for an ideal regimen. No data clearly support the use of aspirin,
heparin, or dextran in perioperative anticoagulation in microsurgical free-tissue transfers.
Current methods of anticoagulation in microvascular surgery have not been found to be
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consistent in their efficacy and profile of adverse effects. Specifically, aspirin, heparin, and
dextran have all varied greatly in their results in animal trials compared with prospective
and retrospective clinical trials in humans. In addition, the pleiotropic effects of statins have
raised the question whether statins could be beneficial in the prevention of microvascular
thrombosis after free-tissue transfers.49,106,107
Since the approval of the first HMG-CoA reductase inhibitor lovastatin in 1987, statins
have been prescribed to more than 1 million patients and are generally considered to be safe
and efficacious pharmaceutical agents. By inhibiting mevalonic acid, the downstream ef-
fects of statins include reduction of inflammation, reduced thrombogenicity, and improved
vasodilation. However, over the course of the last 2 decades, side effects, particularly rhab-
domyolysis and adverse effects on liver, were noted in several trials. The incidence of
myalgia reported in the literature is said to occur in about 5% of cases, whereas true cases
of rhabdomyolysis range from 0.1% to up to 0.2% combined with side effects of additional
pharmaceutical agents. Equally prevalent is the notion that statins cause adverse effects
on the liver. Most reports of liver failure were reported in isolated case reports. How-
ever, a large trial following 23,000 patients on statins noted a significant increase in alanine
aminotransferase on only 0.3% of the enrolled patients, disputing the idea that statins caused
severe injury to the liver.108 In comparison with aspirin, heparin, and dextran, statins have
not been shown to pose any increased risk of bleeding or impairment of liver function.
In addition, other major adverse effects, such as heparin-induced thrombocytopenia, pul-
monary edema, or nephrotoxicity, as seen with heparin or dextran, are not a part of the risk
profile.
Given the fact that improvement in endothelial dysfunction is seen prior to and inde-
pendent of changes in lipid concentrations, we postulate that statin therapy has the potential
to increase endothelial NO bioavailability in zones of mechanical or ischemic injury in the
microcirculation, leading to vasodilatation and further reduction in microvascular throm-
bosis. Not only is this effect theoretically possible in free-tissue transfers but also in the
microvasculature of local and regional tissue rearrangements.
There is a limited body of evidence supporting the use of statins as anticoagulants in
free flap surgery. In a review of the surgical literature, Williams and Harken109 conclude
that postoperative mortality could be reduced with statin use. A well-designed prospective
randomized study with atorvastatin in elective vascular surgery yielded results that showed
an event incidence rate marked by nonfatal myocardial infarction, stroke, and death of 3
times higher for patients treated with placebo versus patients treated with atorvastatin.110
An often-cited meta-analysis by Hindler et al111 states that both cardiac and general surgery
patients show better clinical outcomes with the addition of statins. Despite a limited
body of evidence, Karsenti and colleagues107 have proposed and instituted a preoperative
2-week treatment protocol with statins, adding 40 mg of atorvastatin per day to all free flap
surgical procedures. In addition, the administration of atorvastatin is continued through the
postoperative period until complete stabilization of the patient.107 Although the data are
promising, we argue that a better understanding of the molecular pathways and expression
of molecular factors involved in vasoreactivtiy, thrombosis, and inflammation in free flap
surgery is needed before starting empirical treatment with statins. A start with animal mod-
els to assess the effects of statins on the site of vascular anastomosis and to study the effects
on ischemia and injury should be attempted prior to any large trails or empirical treatment.
An equally important aspect of statin treatment is the cost-effectiveness of such therapy.
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Well-designed studies marked by a primary endpoint of free flap survival with statin treat-
ment are also needed to determine the number needed to treat and the cost-effectiveness of
statin treatment in free flap surgery.
CONCLUSION
The trend toward more elective microsurgery, in combination with the clear molecular
pathway behind the effects of satins, suggests that placing patients with elective free flap
taking statins as a part of their normal perioperative routine may be advantageous. With
low complication rates, statins offer a relatively benign intervention that may significantly
benefit microsurgeons and patients alike. Studies need to be conducted to determine the
optimal pre- and postoperative treatment length and dose of statin therapy.
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